THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB and has been sold online as a 1 receptor designer drug.   
It is a
structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
Pharmacology [ edit ]
THJ-2201 acts as a
full agonist with a binding affinity of 1.34nM at CB and 1.32nM at 1 CB 2 cannabinoid receptors.
Side effects [ edit ]
THJ-2201 has been linked to at least one hospitalization and death due to its use.
Legal status [ edit ]
Because of the hazards associated with recreational use of this compound,
it is classified as a  Schedule I controlled substance in the United States.
It is also an
Anlage II controlled drug in Germany.
See also [ edit ]
References [ edit ]
Xingxing Diao; Ariane Wohlfarth; Shaokun Pang; Karl B. Scheidweiler; Marilyn A. Huestis (October 2015). "High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes". Clinical Chemistry. doi: 10.1373/clinchem.2015.243535. PMID 26430074.
Shevyrin, Vadim; Melkozerov, Vladimir; Nevero, Alexander; Eltsov, Oleg; Morzherin, Yuri; Shafran, Yuri (2014). "3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: Chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures". Forensic Science International. 242: 72–80. doi: 10.1016/j.forsciint.2014.06.022. PMID 25036783.
Nahoko Uchiyama; Yoshihiko Shimokawa; Maiko Kawamura; Ruri Kikura-Hanajiri; Takashi Hakamatsuka (August 2014). "Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products". Forensic Toxicology. 32 (2): 266–281. doi: 10.1007/s11419-014-0238-5.
Xingxing Diao; Karl B. Scheidweiler; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marilyn A. Huestis (2016). "Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes". Forensic Toxicology. 34: 256–267. doi: 10.1007/s11419-016-0312-2. PMC . 4971051
"THJ-2201". Cayman Chemical . Retrieved . 21 July 2015
Hess, Cornelius; Schoeder, ClaraT.; Pillaiyar, Thanigaimalai; Madea, Burkhard; Müller, ChristaE. (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi: 10.1007/s11419-016-0320-2. ISSN 1860-8965. PMC . 4929166 PMID 27429655.
Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi: 10.1056/NEJMp1505328. PMID 26154784.
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration (December 2014). "N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3- carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- indazole-3-carboxamide (AB-PINACA) and [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone (THJ-2201): Background Information and Evaluation of 'Three Factor Analysis' (Factors 4, 5, and 6) for Temporary Scheduling" (PDF).
Drug Enforcement Administration, Department of Justice (2015). "Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order". Federal Register. 80 (20): 5042–7. PMID 25730924.
"Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)" . Retrieved . 9 July 2015